Clinical Trial Protocol

Trial Title: An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis

Protocol Number: RITAZAREM

EudraCT Number: 2012-001102-14

ClinicalTrials.gov: 

Investigational Product: Rituximab

Protocol Version: 1.1 19th July 2012

Chief Investigators: Dr David Jayne  Dr Peter Merkel

CI Address: Box 57, Vasculitis Office  Division of Rheumatology
Addenbrooke’s Hospital  University of Pennsylvania
Hills Road  3400 Spruce St, Penn Tower 8th fl
Cambridge, CB2 0QQ  Philadelphia, PA 19104
United Kingdom  United States of America

Telephone: 00 44 1223 586796 00 1 215 614 4401

Trial Sponsor: Cambridge University Hospitals NHS Foundation Trust (Rest of World)

North American Sponsor: University of Pennsylvania (US and Canada)

Funding: Arthritis Research UK, U.S. National Institutes of Health, and Roche/Genentech

RITAZAREM is a joint venture of the European Vasculitis Study Group (EUVAS) and the Vasculitis Clinical Research Consortium (VCRC).

SAE Reporting: Dr Michelle Lewin, RITAZAREM UK Trial Coordinator
Vasculitis Research Office, Box 57
Addenbrooke’s Hospital
Hills Road
Cambridge, CB2 0QQ,
United Kingdom.
Telephone: 00 44 1223 349350
Fax: 00 44 1223 586767
Email: michelle.lewin@addenbrookes.nhs.uk

Carol McAlear, RITAZAREM US Trial Coordinator
University of Pennsylvania
8th Floor Penn Tower
3400 Spruce Street
Philadelphia, PA 19104
Telephone: 00 1 781 321 4567
Fax: 00 1 215-614-4402
Email: cmcalear@upenn.edu
1 Protocol Signatures:
I give my approval for the attached protocol entitled “An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis” Version 1.1 dated 19th July 2012.

Chief Investigators

Name: Dr David Jayne Dr Peter Merkel
Signatures: ___________________________ ___________________________
Date: ___________________________ ___________________________

Site Signatures

I have read the attached protocol entitled “An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis” Version 1.1, dated 19th July 2012 and agree to abide by all provisions set forth therein.


I agree to ensure that the confidential information contained in this document will not be used for any other purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of the Sponsor

Principal Investigator

Name: _______________________________________
Signature: _______________________________________
Date: _______________________________________

RITAZAREM
Version Number: 1.1
Date: 19th July 2012
2 Trial Management Committee and Protocol Contributors

Dr David Jayne (Chair/Principal and Chief investigator)
Dr Peter Merkel (Principal and Chief Investigator)
Dr Rona Smith (Trial Physician)
Dr Ulrich Specks
Dr Rachel Jones
Dr Simon Bond (Statistician)
Dr Michelle Lewin (Trial Co-ordinator, UK)
Carol McAlear (Trial Co-ordinator, US)

Industry Partners
Dr. Paul Brunetta and Mr. David Metzer at Roche/Genentech
Lykke Gylvin Hinsch (Roche)
3 Table of Contents

1 Protocol Signatures: ................................................................. 3
2 Trial Management Committee and Protocol Contributors .................. 4
3 Table of Contents .................................................................. 5
4 Abbreviations and Definitions .................................................. 7
5 Trial Synopsis ....................................................................... 8
6 Trial Flow Chart .................................................................. 13
7 Introduction .......................................................................... 14
   7.1 Background ..................................................................... 14
   7.2 Data from Non-Clinical Studies ......................................... 14
   7.3 Clinical Data .................................................................... 15
8 Rationale for Trial .................................................................. 16
9 Trial Design .......................................................................... 16
   9.1 Statement of Design .......................................................... 16
   9.2 Number of Centres ............................................................ 16
   9.3 Number of Subjects ........................................................... 16
   9.4 Trial Duration ................................................................... 17
   9.5 Trial Objectives ................................................................. 17
   9.6 Trial Endpoints .................................................................. 17
10 Selection and Withdrawal of Subjects and Randomisation ............... 18
   10.1 Inclusion Criteria ............................................................. 18
   10.2 Exclusion Criteria ............................................................ 18
   10.3 Assignment and Randomisation Number ............................. 19
   10.4 Method of Blinding ........................................................... 20
   10.5 Subject Withdrawal Criteria .............................................. 20
11 Trial Treatments .................................................................... 20
   11.1 Rituximab ...................................................................... 20
   11.2 Azathioprine ................................................................... 22
   11.3 Methotrexate ................................................................... 23
   11.4 Mycophenolate Mofetil ....................................................... 24
   11.5 Rituximab: Presentation of the Drug .................................... 24
   11.6 Known Drug Reactions & Interaction with Other Therapies .... 25
   11.7 Dosage Modifications ....................................................... 25
   11.8 Legal Status of the Drug .................................................... 25
   11.9 Drug Storage and Supply .................................................. 25
   11.10 Concomitant Therapy ....................................................... 23
   11.11 Treatment of relapse ....................................................... 25
12 Procedure and Assessments ...................................................... 27
   12.1 Screening Evaluation ....................................................... 27
   12.2 Baseline Data ................................................................... 27
   12.3 Trial Assessments ............................................................ 28
   12.4 Long-Term Follow-up Assessments .................................... 28
   12.5 Trial Restrictions ............................................................. 28
13 Assessment of Safety ................................................................ 28
   13.1 Definitions ...................................................................... 28
   13.2 Expected Serious Adverse Drug Reactions ............................ 29
   13.3 Expected Serious Adverse Events ....................................... 30
   13.4 Recording and Evaluation of Adverse Events ...................... 31
   13.5 Reporting Serious Adverse Events ..................................... 32
   13.6 Reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs) ... 32
14 Toxicity – Emergency Procedures .............................................. 34
15 Evaluation of Results ........................................................................................................34
  15.1 Response Criteria ........................................................................................................34
16 Statistics ..........................................................................................................................34
  16.1 Statistical Methods ........................................................................................................34
  16.2 Interim Analyses ...........................................................................................................35
  16.3 Number of Subjects to be Enrolled .............................................................................35
  16.4 Criteria for the Termination of the Trial .................................................................35
  16.5 Procedure to Account for Missing or Spurious Data ..............................................35
  16.6 Definition of the End of the Trial ..............................................................................36
17 Data Handling and Record Keeping ...............................................................................36
  17.1 CRF ............................................................................................................................36
  17.2 Source Data ................................................................................................................36
  17.3 Data Protection ............................................................................................................36
18 Data Monitoring Committee/Trial Steering Committee .................................................36
19 Ethical & Regulatory Considerations ............................................................................36
  19.1 Consent ........................................................................................................................36
  19.2 Ethical Committee Review ........................................................................................37
  19.3 Regulatory Compliance ..............................................................................................37
  19.4 Protocol Amendments .................................................................................................37
  19.5 Peer Review ................................................................................................................37
  19.6 Declaration of Helsinki and ICH Good Clinical Practice ........................................38
  19.7 GCP Training ..............................................................................................................38
20 Sponsorship, Financial and Insurance ..........................................................................38
21 Monitoring, Audit & Inspection ......................................................................................38
22 Protocol Compliance and Breaches of GCP ...............................................................38
23 Publications policy .........................................................................................................39
24 Publications
25 Appendices
  25.1 Appendix 1: Schedule of events
4  Abbreviations and Definitions

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAV</td>
<td>ANCA-associated vasculitis</td>
</tr>
<tr>
<td>ANCA</td>
<td>Anti-neutrophil cytoplasmic antibody</td>
</tr>
<tr>
<td>BVAS/WG</td>
<td>Birmingham Vasculitis Activity Score for Wegener’s</td>
</tr>
<tr>
<td>CA</td>
<td>Competent Authority</td>
</tr>
<tr>
<td>CCTU</td>
<td>Cambridge Clinical Trials Unit</td>
</tr>
<tr>
<td>CDA</td>
<td>Combined Damage Assessment Index</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>COPD</td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DSMB</td>
<td>Data Safety and Monitoring Committee</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee (encompassing Institutional Review Board (IRB) and Independent Ethics Committee (IEC))</td>
</tr>
<tr>
<td>EQ5D</td>
<td>EuroQol 5D Quality of Life Questionnaire</td>
</tr>
<tr>
<td>GC</td>
<td>Glucocorticoids</td>
</tr>
<tr>
<td>GP</td>
<td>General Practitioner</td>
</tr>
<tr>
<td>GPA</td>
<td>Granulomatosis with polyangiitis (Wegener’s)</td>
</tr>
<tr>
<td>HACA</td>
<td>Human Antichimeric antibodies</td>
</tr>
<tr>
<td>ICH-GCP</td>
<td>International Conference on Harmonisation – Good Clinical Practice</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent Ethics Committee</td>
</tr>
<tr>
<td>IRB</td>
<td>Independent Review Board</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>MHRA</td>
<td>Medicines and Healthcare products Regulatory Agency</td>
</tr>
<tr>
<td>MMF</td>
<td>Mycophenolate Mofetil</td>
</tr>
<tr>
<td>MPA</td>
<td>Microscopic Polyangiitis</td>
</tr>
<tr>
<td>mRNA</td>
<td>Messenger RNA</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>Research and Development</td>
</tr>
<tr>
<td>REC</td>
<td>Research Ethics Committee</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SmPC</td>
<td>Summary of Product Characteristics</td>
</tr>
<tr>
<td>SUSAR</td>
<td>Suspected Unexpected Serious Adverse Reaction</td>
</tr>
<tr>
<td>TMC</td>
<td>Trial Management Committee</td>
</tr>
<tr>
<td>TPMT</td>
<td>Thiopurine Methyltransferase</td>
</tr>
<tr>
<td>VCRC</td>
<td>Vasculitis Clinical Research Consortium</td>
</tr>
</tbody>
</table>

Definitions

<table>
<thead>
<tr>
<th>Definition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relapse (flare)</td>
<td>The occurrence of any new BVAS/WG item.</td>
</tr>
<tr>
<td>Major Relapse</td>
<td>The development of a new or recurrent major disease activity item using the BVAS/WG assessment tool</td>
</tr>
<tr>
<td>Minor Relapse</td>
<td>Any increase in disease activity that does not meet the definition of Major Relapse</td>
</tr>
<tr>
<td>Remission</td>
<td>BVAS/WG≤1 (one minor persistent BVAS/WG item) and GC dose ≤10mg/day</td>
</tr>
<tr>
<td>Complete Remission</td>
<td>BVAS/WG = 0 independent of GC</td>
</tr>
<tr>
<td>Sustained Remission</td>
<td>Remission lasting more than 6 months without a flare</td>
</tr>
</tbody>
</table>
5 Trial Synopsis

<table>
<thead>
<tr>
<th>Title</th>
<th>An international, open label, randomised, controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis (AAV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor name</td>
<td>Cambridge University Hospitals NHS Foundation Trust University of Pennsylvania</td>
</tr>
<tr>
<td>Disease Under Investigation</td>
<td>Relapsing ANCA-associated vasculitis (AAV)</td>
</tr>
<tr>
<td>Purpose of Clinical Trial</td>
<td>To demonstrate the superiority of rituximab against azathioprine in the prevention of disease flare in AAV patients with relapsing disease</td>
</tr>
<tr>
<td>Clinical Phase</td>
<td>III (3)</td>
</tr>
<tr>
<td>Trial Design</td>
<td>Multi-centre, international, open-label, randomised controlled trial in relapsing AAV. 160 participants will be randomised 1:1 to receive fixed-interval repeat rituximab dosing or azathioprine maintenance therapy</td>
</tr>
<tr>
<td>Primary objective</td>
<td>To demonstrate the superiority of rituximab against azathioprine in the prevention of disease flare in AAV patients with relapsing disease</td>
</tr>
</tbody>
</table>
| Secondary objectives | To demonstrate:  
1. Sustained disease remission beyond the 24 month treatment period  
2. Long term safety of rituximab administration  
3. The optimal remission maintenance therapy in AAV following induction of disease remission with rituximab |
| Trial Endpoints | Primary:  
Time to disease relapse (either minor or major relapse) from randomisation.  
Secondary:  
1. Proportion of patients who maintain remission at 24 and 48 months  
2. Time to a major or second minor relapse  
3. Cumulative accrual of damage as measured by the combined damage assessment score (CDA)  
4. Health-related quality of life as measured using SF-36  
5. Cumulative glucocorticoid exposure  
6. Severe adverse event rate  
7. Infection (treated with either intravenous or oral antibiotics) rate  
Exploratory:  
1. Health economic assessment based on |
<table>
<thead>
<tr>
<th>EQ5D</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Serum rituximab levels, and correlation with circulating B cell</td>
</tr>
<tr>
<td>counts including key subsets and immunoglobulin levels</td>
</tr>
<tr>
<td>3. Changes in ANCA titres (both anti-MPO and anti-PR3 subsets) in</td>
</tr>
<tr>
<td>relation to treatment, response, and relapse.</td>
</tr>
<tr>
<td>4. HACA rate and levels</td>
</tr>
<tr>
<td>5. Serum will be stored for future biomarker studies</td>
</tr>
<tr>
<td>6. mRNA will stored for disease and inflammatory gene activation</td>
</tr>
<tr>
<td>studies</td>
</tr>
<tr>
<td>7. DNA will be stored for future genetic studies</td>
</tr>
</tbody>
</table>

**Sample Size**

Enrolment will be ongoing until 160 patients are randomised. We anticipate this will require 190 patients to be recruited.

**Summary of Eligibility Criteria**

Subjects must meet all of the following criteria to be eligible for enrolment:

1. Written informed consent (15 years and above)
2. A diagnosis of AAV (granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis), according to the definitions of the Chapel Hill Consensus Conference
3. Current or historical ANCA positivity either by ELISA or immunofluorescence.
4. Disease relapse defined by one major or three minor disease activity items on the Birmingham Vasculitis Activity Score for Wegener's (BVAS/WG), in patients that have previously achieved remission following induction therapy

**Key Exclusion Criteria**

1. Age < 15 years (age < 18 years at centres that do not treat paediatric patients)
2. Previous therapy with any biological B cell depleting agent (such as rituximab or belimumab) within the past 6 months

**Investigational Medicinal Product and Dosage**

**Rituximab**

*Induction Regimen*

Patients will be recruited at the time of relapse. All will receive rituximab 375 mg/m²/week x 4 doses and glucocorticoids.
Patients that achieve disease control (BVAS/WG ≤ 1 and daily prednisone dose ≤ 10mg) by month 4 will be randomised to the rituximab or control remission maintenance groups.

**Rituximab maintenance group**
Rituximab 1000 mg at months 4, 8, 12, 16 and 20 and glucocorticoids.

### Active Comparator Products

**Azathioprine**

**Induction Regimen**
Patients will be recruited at the time of relapse. All will receive rituximab 375 mg/m²/week x 4 and glucocorticoids.

Those patients that achieve disease control (BVAS/WG ≤ 1 and daily prednisone dose ≤ 10 mg) by month 4 will be randomised to the rituximab or control remission maintenance groups.

**Control maintenance group**

Azathioprine 2 mg/kg/day from month 4 to 24. Methotrexate 25 mg/week, for patients with GFR > 50 ml/min and intolerant of azathioprine even at a reduced dose of 1 mg/kg/day, or mycophenolate mofetil 2 g/day, for patients intolerant of azathioprine and with GFR < 50 ml/min, and glucocorticoids. Dose reductions for intolerance, abnormal liver function, advanced age, cytopenias, or based on TPMT genetic/activity testing (if performed) will be made. Intolerance is defined as the occurrence of an adverse effect (see section 11.2.i) NOT lack of efficacy. At month 24, the azathioprine dose will be reduced by 50% and stopped at month 27 (dose = 0 mg/day at month 27).

### Route of Administration

Rituximab will be administered intravenously. Azathioprine and mycophenolate mofetil will be administered orally. Methotrexate can be given orally, subcutaneously, or intramuscularly.

### Concomitant Therapy

**Glucocorticoids at induction**

For all glucocorticoid dosing, prednisone may be substituted for prednisolone.

The investigator may choose one of two permitted GC regimens:
Oral prednisone (prednisolone will be allowed), commencing at 1.0mg/kg/day, or 0.5mg/kg/day, both reducing to 10mg/day by month 3 (See schedule 1, pg. 26).

Maximum daily dose of GC is 60 mg prednisolone in week 0. Round down to the nearest 5 mg above 20 mg. Round down to the nearest 2.5 mg below 20 mg. GC to be administered in a single daily dose.

Intravenous (IV) GCs are not mandated by the protocol. At the investigator’s discretion, patients may receive up to a maximum cumulative dose of 3000mg IV methylprednisolone, between 14 days prior to enrolment and 7 days after enrolment.

Glucocorticoids in Maintenance Phase:

A GC dose of prednisolone 10 mg/day or less is a requirement for randomisation. GC reduces to 5 mg/day by month 6, according to schedule 2 (pg. 26). At month 16, GC dose is reduced to 2.5mg/day and at month 20 GC are completely withdrawn.

<table>
<thead>
<tr>
<th>Maximum Treatment Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment is protocolised for the entire duration of the study, until the common close date, when the final patient recruited has completed 36 months within the study or until the patient has completed 48 months on study whichever the sooner. Patients in the rituximab arm will receive treatment until month 20, and those in the azathioprine arm until month 27.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Summary of Study Procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Screening:</strong> Procedures to establish inclusion/exclusion criteria.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Baseline:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline data will include:</td>
</tr>
<tr>
<td>1. Date of birth, sex, limited medical history</td>
</tr>
<tr>
<td>2. Medications, including prior AAV treatments</td>
</tr>
<tr>
<td>3. Height/weight</td>
</tr>
<tr>
<td>4. Disease activity assessment (BVAS/WG)</td>
</tr>
<tr>
<td>5. Disease related damage assessment (CDA)</td>
</tr>
<tr>
<td>6. Patient self reported SF-36 questionnaire and EQ5D questionnaire.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment period:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluations will be performed at months 0, 1.5, 3, 4, 8, 12, 16, 20, 24, 27, 30, 36, and every 6 months until the last patient has</td>
</tr>
</tbody>
</table>
completed 36 months in the study). The maximum duration in the study is 48 months. Assessments will also be performed at the time of relapse or study termination/withdrawal.

<table>
<thead>
<tr>
<th>End of Trial:</th>
<th>The trial will end when the last patient has completed 36 months in the trial.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safety and Monitoring</strong></td>
<td>The NIH-sponsored VCRC Data and Safety Monitoring Board will provide independent oversight of this trial.</td>
</tr>
</tbody>
</table>
6 Trial Flow Chart

Screening and Enrolment

Induction therapy with rituximab (4 x 375mg/m²) and GC

Randomisation

At 4 months for patients demonstrating disease control (BVAS/WG ≤ 1 and GC dose ≤ 10mg per day)

Rituximab Maintenance

1g at 4, 8, 12, 16 & 20 months
Standardised GC taper

Azathioprine Maintenance

2mg/kg/day
Standardised GC taper

Follow-Up Phase

No therapy
Follow-up to between 36 months (min) and 48 months (max)

Follow-Up Phase

Azathioprine withdrawal month 27
Follow-up to between 36 months (min) and 48 months (max)
7 Introduction

7.1 Background

ANCA-associated vasculitis (AAV): Disease overview and current treatment

Granulomatosis with polyangiitis (GPA) (formally Wegener’s granulomatosis (WG)) and microscopic polyangiitis (MPA) are primary systemic vasculitides, predominantly involving microscopic blood vessels with no or scanty immune deposits. Their association with circulating auto-antibodies to neutrophils (ANCA) has led to these conditions being grouped together as ANCA-associated vasculitis (AAV) (1, 2). The cause of AAV is unknown. AAV has an annual incidence of 20 per million and an approximate prevalence of 200/million (3). It is a multi-system autoimmune disease that causes tissue damage especially to the respiratory tract and kidneys, and causes early mortality, organ failure including end stage renal disease, and chronic morbidity. Prior to the availability of effective treatment, AAV was almost universally fatal, with a 93% mortality within 2 years due to pulmonary and renal failure (4). The introduction of what is now termed conventional immunosuppressive treatment transformed survival. Administration of cytotoxic immunosuppression (cyclophosphamide or methotrexate) and corticosteroids for at least one year induces remission in approximately 80% of patients. However, there are a significant proportion of patients that inadequately respond to traditional therapy. Also, relapsing disease is common with over 50% of patients experiencing a relapse within 5 years (5, 6, 7, 8). Relapse is associated with increased exposure to immunosuppressive medications and corticosteroids and at least 25% suffer severe early or late toxicity from these agents (9). The majority of relapses in the NORAM trial were minor, but were associated with a higher cumulative cyclophosphamide and glucocorticoid exposure (submitted 2011). As treatment exposure is the greatest modifiable cause of damage, then prevention of relapses, minor as well as major is highly desirable. There is a major unmet need for safer therapy that leads to sustained treatment free remission in patients with relapsing disease, which will reduce drug toxicity that results from cumulative exposure to cyclophosphamide and glucocorticoids.

Rituximab

Rituximab is an IgG1 kappa, chimeric murine/human monoclonal antibody directed against the B-cell surface molecule CD20, resulting in B cell depletion. CD20 is thought to regulate an early step in the activation process for cell cycle initiation and differentiation. CD20 is not found on pro- or pre-B cells or mature plasma cells (the source of 95% of circulating IgG), so rituximab eliminates peripheral B cells without preventing regeneration of B cells from precursors and does not directly affect immunoglobulin levels. The cytotoxic effect is achieved by antibody-dependent cell-mediated cytotoxicity (ADCC), complement-mediated cell lysis and apoptosis (10). Rituximab was licensed for the treatment of non-Hodgkin’s lymphoma in 1997 and for rheumatoid arthritis in 2006. Rituximab was licensed for AAV by the US FDA in 2011. In these conditions, rituximab was well tolerated with a favourable safety profile.

7.2 Data from Non-Clinical Studies

In vivo preclinical studies have shown that rituximab depletes >95% B cells from the peripheral blood cynomolgus monkeys. This depletion occurs presumably through complement and cell-mediated processes. The B-cell compartments within lymphatic tissue, including spleen, mandibular lymph node, and/or sub-mucosal lymphoid nodules, were also depleted within a short period of treatment, but to a lesser extent. Consistent with rituximab binding only to CD20+ B cells, T cell numbers were unaffected after treatment with rituximab.
7.3 Clinical Data

7.3.1 Efficacy

**Rationale for the use of rituximab in AAV**

B cells play a key role in the pathogenesis of AAV. Not only are they the precursors of ANCA secreting plasma cells, but they also act as antigen presenting cells for autoreactive T cells, providing co-stimulatory support and initiating T cell activation, as well as producing pro-inflammatory cytokines, such as IL-6 and TNFα. Specifically depleting B cells with targeted biological agents, such as rituximab, is therefore a promising approach to the treatment of AAV.

**Rationale for clinical trial design and dosage**

**Rituximab in AAV: Remission induction therapy**

Randomised controlled trial data on the efficacy of rituximab in AAV is available from the RITUXVAS (n=44) (11) and RAVE (n=197) (12) studies. Both compared a rituximab based regimen to a cyclophosphamide based regimen as induction therapy for AAV. The RITUXVAS trial included newly diagnosed renal AAV. RAVE included patients with new and relapsing AAV. Neither trial identified differences in remission or severe adverse event rates between groups. However, the RAVE study included patients with an existing diagnosis of AAV, experiencing disease relapse, as well as those with a new diagnosis. It was in this subgroup of 101 patients that rituximab demonstrated superiority to cyclophosphamide in a prespecified exploratory analysis, with 62.2% patients in the rituximab group entering complete remission, when compared with 42% in the cyclophosphamide group (12).

**Rituximab in AAV: Remission maintenance therapy**

Results from uncontrolled studies consistently suggest that after a single course of rituximab AAV remissions occur and are sustained without the need for maintenance immunosuppression. However the majority of relapsing AAV patients treated with rituximab will relapse, with a mean time to relapse of one year (13). ANCA and B cell levels however lack the sensitivity to predict relapses and guide the timing of re-treatment.

Pilot data on the efficacy of rituximab as a maintenance agent is available from a cohort of 84 patients followed up at Addenbrooke’s hospital between 2002 and 2010. Between 2002 and 2006, 34 patients received non protocolised treatment with rituximab which involved either, 2x1g doses, or 4x375mg/m² doses at the outset, and only further treatment with rituximab if a clinical relapse occurred. From 2006-2011, 50 patients received a protocolised course of rituximab therapy comprising of 2x1g or 4x375mg/m² doses initially, followed by 1g every 6 months for 2 years. Relapse free survival in the protocolised group was considerably higher than that in the non-protocolised group (Figure 1) (Submitted to Arthritis Rheumatism 2011).Six monthly re-treatment with rituximab resulted in prolonged B cell depletion, without a significant fall in immunoglobulin levels or an increased risk of severe adverse events or serious infections.
8 Rationale for Trial

Rituximab is an established induction agent in AAV, especially for those with relapsing disease. Its role as a maintenance agent is less clear. 50% will pursue a chronic relapsing course with 77% relapsing a second time within 2 years of a single course of rituximab. Therefore the major unmet need is prevention of future relapse in relapsing patients. Pilot data suggests that 6 monthly rituximab over 2 years is effective, safe, and leads to sustained treatment free remission. This is the platform for definitive study in a controlled trial which, if positive, will re-define remission therapy for AAV. Relapses however did still occur, the vast majority (90%) within the 2 months preceding subsequent rituximab doses, and so a 4 monthly repeat dosing strategy has been adopted for the study.

The study aims to improve outcomes for AAV patients by comparing a rituximab regimen to the current standard of care – azathioprine or methotrexate and glucocorticoids. In addition to answering the primary question of which is the superior therapy for preventing relapse in AAV, a number of key secondary questions will be addressed:

- Does sustained rituximab therapy have long-term benefit beyond the treatment period?
- Is sustained rituximab safe?
- What is the optimal remission therapy after rituximab induction?

9 Trial Design

9.1 Statement of Design

RITAZAREM is a multi-centre, international, open label, randomised controlled trial in relapsing AAV. Patients will be randomised, 1:1, to receive fixed interval repeat rituximab dosing or azathioprine maintenance therapy.

9.2 Number of Centres

RITAZAREM is a joint venture of the European Vasculitis Study Group (EUVAS) and the Vasculitis Clinical Research Consortium (VCRC).

RITAZAREM will occur in multiple centres internationally including Europe, North America and Australia/New Zealand. Approximately 45 centres are planned to recruit patients.

9.3 Number of Subjects

Enrolment will be ongoing until 160 patients are randomised. We anticipate this will require 190 patients to be recruited. Any patients in the induction phase when

![Figure 1.](image-url) At 24 months, 24% (12/50) of protocolised patients have relapsed, compared to 71% (24/34) non-protocolised patients
enrolment is halted will continue to follow the protocol and be randomised if the relevant criteria are met.

9.4 Trial Duration
The trial has 3 phases and will last for 48 months:

*Induction* – 0-4 months
*Maintenance* – 4-24 months
*Long-term follow-up* – patients will have a minimum of 12, and maximum of 24 months follow-up

9.5 Trial Objectives

9.5.1 Primary objective
To assess whether or not rituximab is superior to azathioprine in the prevention of disease relapse in AAV patients with relapsing disease

9.5.2 Secondary objectives
To demonstrate
1. Sustained disease remission beyond the 24 month treatment period
2. Long term safety of rituximab administration
3. The optimal remission maintenance therapy in AAV following induction of disease remission with rituximab

9.6 Trial Endpoints

9.6.1 Primary endpoint
The primary endpoint is the time to disease relapse (either minor or major relapse) from randomisation. Any patients who have not relapsed at study close will be censored. Further details of how relapse/censoring dates will be defined are given below.

<table>
<thead>
<tr>
<th>Situation</th>
<th>Date of Relapse or Censoring</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>No baseline assessments</td>
<td>Randomization</td>
<td>Censored</td>
</tr>
<tr>
<td>Relapse documented between scheduled visits</td>
<td>Unscheduled visit date</td>
<td>Relapsed</td>
</tr>
<tr>
<td>Drop-out with no relapse</td>
<td>Date of last assessment with no documented relapse</td>
<td>Censored</td>
</tr>
<tr>
<td>Treatment discontinuation for undocumented relapse</td>
<td>Date of last assessment with no documented relapse</td>
<td>Censored</td>
</tr>
<tr>
<td>Treatment discontinuation for toxicity or other reason, or protocol deviation</td>
<td>The patient will be followed up as per protocol and date of relapse or censoring observed accordingly</td>
<td>Relapsed/censored</td>
</tr>
<tr>
<td>Death due to relapse</td>
<td>Date of Death</td>
<td>Relapsed</td>
</tr>
<tr>
<td>Death due to other causes</td>
<td>Date of Death</td>
<td>Censored</td>
</tr>
<tr>
<td>Death or progression after more than one missed visit</td>
<td>Date of last assessment with no documented relapse</td>
<td>Censored</td>
</tr>
</tbody>
</table>
9.6.2 Secondary endpoints

1. Proportion of patients who maintain remission at 24 and 48 months
2. Time to a major or second minor relapse
3. Cumulative accrual of damage as measured by the combined damage assessment score (CDA)
4. Health-related quality of life as measured using SF-36
5. Cumulative GC exposure
6. Severe adverse event rate
7. Infection (treated with intravenous or oral antibiotics) rates

9.6.3 Exploratory endpoints

1. Health economic assessment based on EQ5D
   EQ5D is a standardised instrument for use as a measure of health outcome, providing a simple descriptive profile and a single index value for health status. It is designed to be completed by patients.
2. Serum rituximab levels and correlation with circulating B cell counts including key subsets and immunoglobulin levels
3. Changes in ANCA titres (both anti-MPO and anti-PR3 subsets) in relation to treatment, response, and relapse
4. HACA rate and level
5. Serum will be stored for future biomarker studies
6. mRNA will be stored for disease and inflammatory gene activation
7. DNA will be stored for various studies

10 Selection and Withdrawal of Subjects and Randomisation

10.1 Inclusion Criteria
To be included in the trial the patient must have:

1. Provided written informed consent (15 years and above)
2. A diagnosis of AAV [granulomatosis with polyangiitis or microscopic polyangiitis], according to the definitions of the Chapel Hill Consensus Conference
3. Current or historical ANCA positivity either by ELISA or immunofluorescence
4. Disease relapse defined by one major or three minor disease activity items on the Birmingham Vasculitis Activity Score for Wegener’s (BVAS/WG), in patients that have previously achieved remission following at least 3 months of induction therapy, with a combination of glucocorticoids and an immunosuppressive agent (cyclophosphamide or methotrexate or rituximab)

All patients will receive induction therapy with rituximab. Only those entering remission by 4 months will be randomised 1:1 to the rituximab or control groups

10.2 Exclusion Criteria
The presence of any of the following will preclude patient inclusion:

3. Age < 15 years (age < 18 years at centres that do not treat paediatric patients)
4. Exclusions related to medication:
   Previous therapy with:
   a. Any biological B cell depleting agent (such as rituximab or belimumab) within the past 6 months
   b. Alemtuzumab or anti-thymocyte globulin (ATG) within the last 12 months
   c. IVIg, infliximab, etanercept, adalimumab, abatacept or plasma exchange in past 3 months
d. Any investigational agent within 28 days of screening, or 5 half lives of the investigational drug (whichever is longer)

5. Exclusions related to general health:
   a. Significant or uncontrolled medical disease not related to AAV, which in the investigators opinion would preclude patient participation
   b. Presence of another multisystem autoimmune disease, including Churg Strauss syndrome, systemic lupus erythematosus, anti-GBM disease, or cryoglobulaemic vasculitis,
   c. Any concomitant condition anticipated to likely require greater than 4 weeks per year of oral or systemic glucocorticoid use and which would preclude compliance with the glucocorticoid protocol (e.g. poorly-controlled asthma, COPD, psoriasis, or inflammatory bowel disease).
   d. History of severe allergic or anaphylactic reactions to humanised or murine chimeric monoclonal antibodies
   e. Known infection with HIV (HIV testing will not be a requirement for trial entry); a past or current history of hepatitis B virus or hepatitis C virus infection.
   f. Ongoing or recent (last 12 months) evidence of active tuberculosis or known active infection (screening for tuberculosis is part of ‘standard of care’ in patients with established AAV) or evidence of untreated latent tuberculosis. Screening for tuberculosis is as per local practice.
   g. History of malignancy within the past five years or any evidence of persistent malignancy, except fully excised basal cell or squamous cell carcinomas of the skin, or cervical carcinoma in situ which has been treated or excised in a curative procedure.
   h. Pregnancy or inadequate contraception in women of childbearing potential
   i. Breast feeding
   j. Medical, psychiatric, cognitive or other conditions that, in the investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study.

6. Exclusion criteria related to laboratory parameters:
   a) Bone marrow suppression as evidenced by a total white count < 4 x10^9/l, haemoglobin < 7 gm/dl or platelet count < 100,000/μl
   b) Aspartate aminotransferase or alanine aminotransferase or amylase > 2.5 times the upper limit of normal, unless attributed to vasculitis

10.3 Assignment and Randomisation Number
The patient will be allocated a unique trial identification number to be used on all trial related material for the patient upon enrolling the patient into the trial. Randomization will be performed by the local investigator or other qualified local research staff **only for those patients that achieve disease control (BVAS/WG ≤ 1 and daily prednisone dose ≤ 10mg) by month 4**. Patients will be randomized by logging into an internet based website provided by the Cambridge Clinical Trials Unit. After logging in, the investigator will confirm eligibility criteria, ANCA subtype, relapse severity and the prednisolone induction regimen followed (1A or 1B).

Patients will be stratified at the time of randomisation according to:
1. ANCA type (anti-PR3 or anti-MPO)
2. Relapse severity (severe or non-severe)
3. Selected prednisone induction regimen (1A or 1B)

The randomization algorithm will then assign the patient to either the rituximab maintenance therapy or the control arm, where patients receive azathioprine, unless
there is a contraindication when mycophenolate mofetil or methotrexate are alternatives (see section 11.1.4). At the point of randomisation the patients’ unique identification number will need to be entered into the randomisation system. Notification of the treatment allocation will be forwarded to the central study coordinator, local investigator and local pharmacy by electronic mail (email) upon randomization. In the event that access to the internet is unavailable, the investigator may call the central study coordinator, based at Addenbrooke’s Hospital, Cambridge, UK who will access the randomization program and inform the investigator of the treatment allocation and ensure randomization information reaches the appropriate study personnel.

A non-blinded, open label study has been chosen for reasons of simplicity and practicality in view of RITAZAREM being an international multi-centre trial. Previous EUVAS studies with similar end-points have also been unblinded yet have led to robust and reproducible conclusions.

10.4 Method of Blinding
This will be an open label study.

10.5 Subject Withdrawal Criteria
Patients will be withdrawn from the trial immediately if they choose to withdraw their consent to participate. Otherwise subjects will be followed until the end of the trial or until death. In the event that consent to participate is withdrawn, we will request that we be allowed to collect vital status information from the patient and/or their family physician or general practitioner. Subjects who are withdrawn will not be replaced. Subjects will not be randomized if they do not achieve disease control (BVAS/WG ≤ 1 and daily prednisone dose ≤ 10mg) by month 4 and will be treated at the discretion of the local investigators, although they will continue to be followed and data collected for safety purposes.

We anticipate withdrawal will be a rare occurrence. Local investigators may stop the randomised treatment for appropriate medical reasons, be that individual adverse events or new information gained about a treatment. Pregnant patients will be treated with best medical practice, and continue in long term follow up. Non-compliant patients will be helped to return to protocol compliance, and continue in long term follow up. Any decision to stop the randomised treatment MUST be discussed with the chief investigator in order not to adversely affect the conduct of the trial. Patients will continue to be followed up, and data collected and documented as set out in the protocol, unless they withdraw their consent for this.

11 Trial Treatments

11.1 Rituximab

Rationale for rituximab dosing
Induction Phase:
375mg/m²/week x 4 doses, was the dose used in both the randomised controlled rituximab induction trials in vasculitis (RITUXVAS and RAVE) and will be the induction dose used in RITAZAREM.

Maintenance Phase:
Neither RITUXVAS nor RAVE addressed the question of repeat dosing with rituximab as a maintenance strategy. The two largest data sets presently available utilising repeat rituximab as a maintenance strategy, employed doses of 1000mg x 2 every 6 months (Mayo Clinic) (total 8000mg in 24 months) or 1000mg every 6 months (Cambridge,
UK) (total 4000mg in 24 months). The selected dose for RITAZAREM, 1000mg every 4 months (5000mg in total), falls between these two regimens. In addition, 9 out of 10 relapses seen in the Cambridge cohort occurred in the 2 months prior to a scheduled rituximab dose, yet responded to further rituximab. Reducing the interval between rituximab doses to 4 months has the potential to further reduce relapse rates.

B cell depletion is a pharmacodynamic surrogate for rituximab efficacy. Because B cell return typically commences after four months, by reducing the dosing interval to four months we aim to maintain 100% B cell depletion for the 24 month treatment phase.

No data exists for a total rituximab dose below 1000mg in vasculitis. Adopting a 375mg/m² dose every 4 months as a maintenance strategy would result in a median dose of 700mg. The MAINRITSAN study is employing a 500mg dose every 6 months. This is likely to result in under dosing, because 20% of patients relapsed using 1000mg every 6 months in the Cambridge cohort. In addition, more frequent maintenance dosing is inconvenient for patients and more expensive.

11.1.1 Dosage schedules

Induction Regimen
Patients will be recruited at the time of relapse. All will receive rituximab 375 mg/m²/week x 4 doses and glucocorticoids.

Patients that achieve disease control (BVAS/WG ≤ 1 and daily prednisone dose ≤ 10mg) by month 4 will be randomised to the rituximab or control remission maintenance groups.

First infusion: The recommended initial infusion rate for MabThera/Rituxan is 50 mg/h; subsequently, the rate can be escalated in 50 mg/h increments every 30 minutes to a maximum of 400 mg/h.

Subsequent infusions: Subsequent infusions of MabThera/Rituxan can be started at a rate of 100 mg/h and increased by 100 mg/h increments every 30 minutes to a maximum of 400 mg/h.

Pre-medication with 100 mg IV methylprednisolone will be administered prior the first infusion to minimise infusion reactions. Sites will follow local pre-medication practice for infusions 2, 3, and 4. 100 mg IV methylprednisolone will be administered prior to each maintenance dose.

Rituximab maintenance group
Rituximab 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids.

11.1.2 Route of Administration
Rituximab will be administered intravenously.

11.1.3 Maximum dosage allowed
The induction dose will vary depending on the body surface area of the patient. The maximum dose administered during the maintenance phase will be 5g.

11.1.4 Maximum duration of treatment of a subject
Treatment with rituximab will cease at month 20. Patients will continue to be followed until month 36 at a minimum.
11.2 Azathioprine
Azathioprine is converted in the liver to 6-mercaptopurine, which impairs purine synthesis, incorporation of purines into DNA and DNA polymerase repair activity. Lymphocyte function is reduced, B cells more than T cells, as well as the cellular component of the inflammatory response. Azathioprine is well absorbed orally, and its elimination requires hepatic metabolism by xanthine oxidase. Therefore an important interaction is with allopurinol, a xanthine oxidase inhibitor.

Patients randomised to the control arm will receive oral azathioprine, to be taken daily. The maximum daily dose allowed is 200mg. The maximum treatment period is 27 months, with tapering at month 24 as described below.

i. Adverse Effects
Major adverse effects include nausea and vomiting, dose-dependent myelosuppression and reversible, cholestatic hepatotoxicity. An increased incidence of malignancy particularly skin cancers and lymphoma has been seen after prolonged administration in transplant recipients.

ii. Administration
The target dose is 2mg/kg. The maximum daily dose is 200mg.
This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.
The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.
If patients are aged over 60 years, reduce the dose by 25%.
If patients are aged over 75 years, reduce the dose by 50%.

iii. Monitoring
Check full blood count (FBC/CBC) and ALT or AST (for hepatotoxicity), every 2 weeks for the first month, then every 2 months for the first year and then every 3 months thereafter.

iv. Leucopenia related to azathioprine
Stop oral azathioprine if the white cell count (WBC) < 4 x 10^9/l
Restart with a dose reduced by 25% when WBC > 4 x 10^9/l. Monitor weekly for four weeks. If leucopenia is severe (WBC < 1 x 10^9/l or < 4 x 10^9/l for more than 2 weeks), restart azathioprine at 50mg per day, when WBC > 4 x 10^9/l. Increase weekly to target dose as WBC allows.
Temporary prophylaxis to prevent PJP (PCP) and fungal infection are recommended until WCC > 4 x 10^9/l. G-CSF may be considered.
For a falling WBC, (<6 x 10^9/l and a fall of > 2 x 10^9/l over the previous count), then reduce dose by 25%.

v. Azathioprine intolerance
Methotrexate 25 mg/week, for patients with GFR > 50 ml/min and intolerant of azathioprine even at a reduced dose of 1 mg/kg/day, or mycophenolate mofetil 2 g/day, for patients intolerant of azathioprine and with GFR < 50 ml/min, and glucocorticoids. Dose reductions for intolerance, abnormal liver function, advanced age, cytopenias, or based on TPMT genetic/activity testing (if performed) will be made.
11.3 Methotrexate
Methotrexate is a folic acid antagonist. Its cytotoxic effect is mediated by binding of dihydrofolic acid reductase, which inhibits the reduction of folic acid to tetrahydrofolate, which is essential for the synthesis of purine and pyrimidine. Methotrexate easily penetrates the tissues after oral administration, with the highest concentrations being seen in the liver and kidneys. Most methotrexate is excreted unchanged through the urine within 24 hours. Renal disease causes accumulation of methotrexate, and in rare cases methotrexate can form complexes in the kidneys leading to renal damage.

Methotrexate is to be taken orally, in a weekly dose. The maximum dose allowed is 25mg/week. The maximum treatment period is 27 months.

i. Adverse Effects
Adverse events include myelosuppression occurring day 7-14 after a single dose, infections due to immunosuppression, stomatitis, gastrointestinal disturbance (nausea, vomiting, diarrhoea), alopecia, hypersensitivity reactions and central nervous systemic disturbance (headaches, drowsiness and blurred vision). Rare, but serious side effects include pulmonary fibrosis and a reversible hepatotoxicity manifest by increased transaminases. Patients should only drink minimal amounts of alcohol, and methotrexate should be avoided if there is pre-existing liver disease. Methotrexate is teratogenic, and therefore adequate contraceptive methods must be employed whilst on the drug and for 3-6 months after stopping it. Concomitant administration of folate antagonists, such as co-trimoxazole and trimethoprim should be avoided, as acute megaloblastic pancytopenia has been reported. As it is renally excreted methotrexate should be avoided in patients with moderate to severe renal impairment.

ii. Administration
Patients commencing methotrexate after induction of remission should start at a dose of 10mg per week. This should increase by 2.5mg weekly to a target dose of 25mg weekly. Folic acid, 5mg weekly, should also be commenced. Methotrexate is given orally, although parenteral, intramuscular, or subcutaneous administration can be used if oral medication is not tolerated. In the case of gastrointestinal disturbance, methotrexate can be given in 2 divided doses on the same day. Metoclopramide can also be administered.

iii. Monitoring
Full blood count (FBC) and liver function tests (LFTs) should be measured every 2 weeks for the first month and then monthly until the dose is stable. Thereafter FBC and LFTs should be monitored 3 monthly, and renal function and electrolytes every 6 months.

Folic acid should be checked monthly for the first year, and then two monthly thereafter.

If transaminases rise > 3 fold of the normal range, or WBC < 3 x 10^9/l or platelet count < 100,000/μl (lasting more than 4 weeks and being attributable to methotrexate therapy), folic acid should be administered orally the day after methotrexate therapy at an equal dose. If the condition is not reversed within 4 weeks, the methotrexate and folic acid dose should be reduced by 50%. If this is not effective, then the methotrexate and folic acid should be stopped. If disease is in remission, and all blood tests have normalised within
4 weeks, then one could consider restarting methotrexate and folic acid at the original dose.

**11.4 Mycophenolate Mofetil**

MMF is a prodrug that is hydrolysed to form mycophenolic acid. Mycophenolic acid reversibly inhibits inosine-monophosphate-dehydrogenase (IMDH), a key enzyme of de novo purine synthesis. Lymphocytes are key effector cells in AAV, whose proliferation and function relies almost exclusively on de novo purine synthesis whereas most other cells use the salvage pathway.

MMF is to be taken orally, twice daily. The maximum dose allowed is 3g/day. The maximum treatment period is 27 months.

i. **Adverse Effects**

Adverse effects of mycophenolate mofetil include gastro-intestinal (GI) disturbance leucopenia and infection including cytomegalovirus (CMV). In a systematic review of transplant patients, leucopenia and CMV were significantly more common only at the very highest MMF dose (3g), compared with azathioprine. The frequency of malignancy in a three year transplant study where MMF was combined with other immunosuppressive drugs showed no difference compared to azathioprine. GI adverse effects may be related to accumulation of the metabolite, mycophenolic acid glucuronide, which accumulates in renal failure. Dose reduction in those with a creatinine clearance of less than 25 ml/min may be required.

ii. **Administration**

Mycophenolate mofetil will be administered orally. The drug will be started at 1g per day and dose increased to the target dose of 2g per day if tolerated. The dose can be increased to 3g daily for those with a sub optimal response.

iii. **Monitoring**

The total white cell count (WBC) must be monitored for patients taking MMF initially weekly for the first month, then alternate weeks for the next two months and then once a month thereafter.

Stop if WBC < 4 x 10^9/l. Restart with MMF dose reduced by at least 500mg when WBC > 4 x 10^9/l. Monitor weekly for one month.

If severe (WBC < 1 x 10^9/l or prolonged (WBC < 4 x 10^9/l for > 2 weeks), MMF should be withdrawn.

**11.5 Rituximab: Warnings and precautions**

Infusion reactions of mild to moderate severity are common and can comprise fever, chills and shivering, nausea and vomiting, itching, changes in blood pressure, headaches, wheezing, hives, muscle pain and dizziness. Their frequency and severity is reduced by pre-medication with anti-histamine, paracetamol and glucocorticoids. Premedication consisting of an analgesic/anti-pyretic (e.g. paracetamol) and an anti-histaminic drug (e.g. diphenhydramine) should always be administered before each infusion of rituximab. Severe infusion reactions are rare and may cause arrhythmia, heart attack, dyspnoea and loss of life. Rituximab has caused skin reactions and flares of psoriasis. In rare cases patients have contracted progressive multifocal leukoencephalopathy, caused by the JC virus, after rituximab. Patients who are carriers for Hepatitis B virus can suffer reactivation of viral infection. Rituximab may increase the risk of severe infection. Rituximab can cause arrhythmias. Patients should not receive live vaccines while taking rituximab. Rituximab can potentially interact with other
medications. Rituximab may not be safe to use in pregnancy and it is unknown whether it passes into the breast milk.

11.6 Known Drug Reactions & Interaction with Other Therapies
Infusion reactions (within 24 hours of the infusion) occur in up to 50% of patients receiving rituximab. Pre-medication with 100 mg IV methylprednisolone will be administered prior the first infusion to minimise the effect of such reactions. Sites will follow local pre-medication practice for infusions 2, 3, and 4. 100 mg IV methylprednisolone will be administered prior to each maintenance dose. Symptoms include – fever, rigors, urticaria/rash, pruritis, flushing, angiodema, nausea, vomiting, fatigue, headache, rhinitis, throat irritation, bronchospasm and hypotension. Following treatment, sepsis, leucopaenia and neutropaenia can occur.

Please also see Summary of Product Characteristics for expected adverse events associated with rituximab administration.

11.7 Dosage Modifications
Rituximab will be administered at a dose of 375mg/m² x 4, at weekly intervals during the induction phase of the trial. Patients achieving remission and randomised to the rituximab remission maintenance group will receive rituximab 1000mg, at months 4, 8, 12, 16 and 20. The dose of rituximab does not need to be adjusted for renal function. Further doses of rituximab will not be administered if IgG levels are less than 3g/l.

11.8 Legal Status of the Drug
Rituximab (Mabthera) has marketing authorisation numbers EU/1/98/067/001 and EU/1/98/067/002, which were granted in the EU to Roche Registration Limited. Rituximab has a license for use in stage III-IV follicular lymphoma (Non-Hodgkins lymphoma) and in chronic lymphocytic leukaemia in both untreated and relapsing/refractory patients. It has a license for use in severe active rheumatoid arthritis, in combination with methotrexate, when patients have had an inadequate response or demonstrated intolerance to other disease modifying agents, including one or more anti-TNF agents.

In the United States rituximab is licensed for use in lymphoma, rheumatoid arthritis, and induction therapy for AAV (with regimen of 375mg/m² x 4 doses).

For further information, please refer to approved local Product Information eg Summary of Product Characteristics (SmPC).

11.9 Drug Storage and Supply
Rituximab must be stored as directed by the relevant SmPC, and the container should be kept in the outer carton to protect from light. Rituximab (MabThera) will be supplied directly by Roche to non-US sites, and Rituximab (Rituxan) to all US sites by Genentech. Trial-specific prescriptions will be used for the entirety of the trial.

11.10 Concomitant Therapy

11.10.1 Glucocorticoids
Glucocorticoids at Induction:
For all glucocorticoid dosing, prednisone may be substituted for prednisolone. The investigator may choose one of two permitted glucocorticoid regimens to allow for variabilities in disease severity and glucocorticoid prescribing.
Oral prednisone (prednisolone will be allowed), commencing at 1.0mg/kg/day, or 0.5mg/kg/day, both reducing to 10mg/day by month 3. We advise starting at 1.0mg/kg/day initially for those with life or organ threatening manifestations, such as severe nephritis or pulmonary haemorrhage and 0.5mg/kg/day for those with less severe disease. However, this is left to physician discretion, although the initial dose MUST be specified on the randomisation form, as it will be a stratification criterion. Regardless of the dose chosen the tapering must adhere to schedule 1 below.

### Schedule 1:

<table>
<thead>
<tr>
<th>Week</th>
<th>Induction Schedule A 1 mg/kg group</th>
<th>Induction Schedule B 0.5 mg/kg group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Weight-adjusted dose (mg/kg)</td>
<td>Actual dose (mg)</td>
</tr>
<tr>
<td>0</td>
<td>1.0</td>
<td>0.5</td>
</tr>
<tr>
<td>2</td>
<td>0.75</td>
<td>0.4</td>
</tr>
<tr>
<td>4</td>
<td>0.5</td>
<td>0.35</td>
</tr>
<tr>
<td>6</td>
<td>0.375</td>
<td>0.3</td>
</tr>
<tr>
<td>8</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>10</td>
<td>12.5</td>
<td>12.5</td>
</tr>
<tr>
<td>12</td>
<td>10</td>
<td>10</td>
</tr>
</tbody>
</table>

The maximum daily dose of prednisolone is 60 mg in week 0. The dose should be rounded down to the nearest 5 mg above 20 mg and to the nearest 2.5 mg below 20 mg. Prednisolone is to be administered in a single daily dose.

Intravenous (IV) GC are not mandated by the protocol. But, at the investigator’s discretion, patients may receive up to a maximum cumulative dose of 3000mg IV methylprednisolone, between 14 days prior to enrolment and 7 days after enrolment.

**Glucocorticoids in Maintenance:**
A GC dose of 10 mg/day or less is a requirement for randomisation. GC reduces to 5 mg/day by month 6, according to schedule 2, and continues at 5 mg daily until month 16. GC dose is then reduced to 2.5mg/day and completely withdrawn at month 20.

### Schedule 2:

<table>
<thead>
<tr>
<th>Week</th>
<th>Maintenance Schedule Daily prednisone dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>14</td>
<td>10</td>
</tr>
<tr>
<td>16 (randomisation)</td>
<td>10</td>
</tr>
<tr>
<td>18</td>
<td>7.5</td>
</tr>
<tr>
<td>20</td>
<td>7.5</td>
</tr>
<tr>
<td>22</td>
<td>5</td>
</tr>
<tr>
<td>24</td>
<td>5</td>
</tr>
</tbody>
</table>

Alternate day dosing regimens (i.e. those that use two different doses on alternate days) may be used to achieve the appropriate average daily dose required by the protocol but differences in alternative day doses may not be >5 mg. For example, a
dose of 7.5 mg/day may be achieved by alternating daily doses of 10 mg/day and 5 mg/day.

**Adverse effects**
The following are expected adverse effects if GC therapy: sepsis, hypertension, fluid retention, hyperglycaemia and diabetes mellitus, peptic ulceration, osteoporosis, avascular necrosis, cushingoid appearance, striae, alopecia and hirsutism.

11.10.2 **Prophylactic therapies**
Prophylaxis for infection, such as with low-dose sulfamethoxazole-trimethoprim and prophylaxis for osteoporosis with calcium and vitamin D supplementation are strongly recommended and treatment with bisphosphonates to be considered but implementation is left to local practice.

11.10.3 **Plasma exchange**
Plasma exchange can be administered during the induction period following local practice at the discretion of the investigator. Rituximab will not be administered within the 48 hours prior to receiving a plasma exchange treatment.

11.11 **Treatment of relapse**
Patients experiencing their first minor relapse after randomisation and before month 24 of the treatment phase will remain on the randomised treatment (rituximab or azathioprine) and will have their oral prednisolone/prednisone increased to 20mg/day for one week decreasing in 2.5mg increments each week to reach 5mg/day after six weeks. The second minor relapse or first major relapse, occurring before month 24 of the treatment phase will result in the patient being withdrawn from protocolised treatment and returned to treatment according to local best practice. Any relapse occurring after the 24 month treatment phase will be treated according to local best medical practice.

12 **Procedure and Assessments**

12.1 **Screening Evaluation**
Patients must review and sign the ICF prior to undergoing any study-related assessment. Patients will be evaluated by their local trial investigators to ensure they meet all the inclusion criteria and none of the exclusion criteria as stated in sections 10.1 and 10.2 of this protocol. The screening visit requires confirmation of the diagnosis of AAV (ANCA positivity, current or historical and pertinent histology results) and documentation of organ manifestations of active AAV. They will then undergo a baseline assessment. Therapy with IV methylprednisolone may begin during screening.

12.2 **Baseline Data**
Baseline data will include basic demographic information, laboratory data and clinical data and will be collected prior to receiving study therapy.

This information will include:
- a) Height and weight
- b) Sex
- c) Age and date of birth
- d) Any significant past medical history
- e) Concomitant medications, including previous treatment for AAV and prior cyclophosphamide exposure
f) Full blood count (including platelets and differential white cell count)
g) Biochemical series (including renal function and immunoglobulin levels)
h) Pregnancy test in females of child bearing potential
i) Viral screen, including hepatitis B and C
j) Disease activity assessment (BVAS/WG) (including urine sample)
k) Damage related assessment (CDA)
l) Patient self-reported SF-36 questionnaire and EQ5D questionnaire

12.3 Trial Assessments

12.3.1 Timing of assessments
Evaluations will be performed at months 0, 1.5, 3, 4, 8, 12, 16, 20, 24, 27, 30, 36, and every 6 months until the last patient has completed 12 months of follow up (36 months from study entry)
Only those patients that achieve disease control (BVAS/WG ≤ 1 and daily prednisone dose ≤ 10mg) by month 4 will be randomised to the rituximab or control remission maintenance groups. Patients who are not randomised will be seen at 6 months and at then at intervals of 6 months until the common study closure date.

12.3.2 Assessment data
The following assessments will be performed at the above time points:
a) Disease activity assessment (BVAS/WG) (including urine sample)
b) Damage related assessment (CDA)
c) Quality of life evaluations – Short form 36 (SF-36) questionnaire and EQ5D questionnaire at months 0, 4, 12, 24 and 36
d) Blood tests including a full blood count and immunoglobulin levels (refer to schedule of assessment, Appendix 1, for collection of biomarker samples for DNA, RNA and serum).
e) Treatment exposure to prednisolone, rituximab and azathioprine
f) Adverse event review and concomitant medication review
The above assessments will also be performed at the time of relapse or study termination/withdrawal.

12.4 Long-Term Follow-up Assessments
All patients will be followed until the last patient to be recruited has completed 36 months from study entry. With a two year recruitment period the median duration of follow-up will be 48 months from entry (range 36-48 months).

12.5 Trial Restrictions
There are no specific restrictions to daily activities for participants of the study. Both male and female subjects should take adequate contraceptive precautions for the duration of the interventional phase of the trial (initial 24 months). In addition, contraception should be continued for 12 months after the last dose of rituximab. No live vaccines should be given to enrolled patients during the first 27 months of the trial.

13 Assessment of Safety

13.1 Definitions
13.1.1 Adverse event
Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational
medicinal product, whether or not considered related to the investigational medicinal product.

13.1.2 **Adverse reaction** to an investigational medicinal product (AR)
All untoward and unintended responses to an investigational medicinal product related to any dose administered. All adverse events judged by either the reporting investigator or the sponsor as having a reasonable causal relationship to a medicinal product qualify as adverse reactions. The expression reasonable causal relationship means to convey in general that there is evidence or argument to suggest a causal relationship.

13.1.3 **Unexpected adverse reaction**
An adverse reaction, the nature, or severity of which is not consistent with the applicable product information (e.g. investigator's brochure for an unapproved investigational product or summary of product characteristics (SmPC) for an authorised product).
When the outcome of the adverse reaction is not consistent with the applicable product information this adverse reaction should be considered as unexpected.

The term "severe" is often used to describe the intensity (severity) of a specific event. This is not the same as "serious," which is based on patient/event outcome or action criteria.

13.1.4 **Serious adverse event (SAE) or serious adverse reaction**
Any untoward medical occurrence or effect that:
- Results in death
- Is life-threatening
- Requires hospitalization or prolongs an existing hospitalization
- Results in persistent or significant disability or incapacity
- Is a congenital anomaly or birth defect

Life-threatening in the definition of a serious adverse event or serious adverse reaction refers to an event in which the subject was at risk of death at the time of event; it does not refer to an event which hypothetically might have caused death if it were more severe.

13.2 Expected Serious Adverse Drug Reactions

**Rituximab**
Infusion reactions (within 24 hours of the infusion) may occur in up to 50% of patients receiving rituximab. Pre-medication with 100 mg IV methylprednisolone will be administered prior the first infusion to minimise the effect of such reactions. Sites will follow local pre-medication practice for infusions 2, 3, and 4. 100 mg IV methylprednisolone will be administered prior to each maintenance dose. Symptoms include – fever, rigors, urticaria/rash, pruritis, flushing, angioedema, nausea, vomiting, fatigue, headache, rhinitis, throat irritation, bronchospasm and hypotension. Following treatment, sepsis, leucopaenia and neutropaenia can occur. However, lower rates were observed in the two randomised controlled induction trials. In the RITUXVAS study, 2/33 patients experienced an infusion reaction and in RAVE, only 1/99 experienced an infusion reaction severe enough to prevent administration of further infusions of rituximab.

**Azathioprine**
The following expected serious adverse drug reactions may occur in patients taking azathioprine: hematotoxicity, hepatotoxicity, pancreatitis and gastrointestinal
disturbances. Hypersensitivity reactions may also occur (including malaise, dizziness, vomiting, diarrhoea, fever, rigors, myalgia, arthralgia, rash, hypotension and interstitial nephritis) and there is increased susceptibility to infections.

**Mycophenolate Mofetil**

Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Mycophenolate Mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin. Patients receiving Mycophenolate Mofetil should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression. Patients treated with immunosuppressants, including Mycophenolate Mofetil, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis. Other suspected serious adverse drug reactions include gastrointestinal disturbance (nausea, constipation, flatulence, anorexia, weight loss, vomiting, abdominal pain, gastro-intestinal inflammation, ulceration, and bleeding, hepatitis, jaundice, pancreatitis) and blood disorders (including leucopenia, anaemia, thrombocytopenia, pancytopenia, and red cell aplasia).

**Methotrexate**

Acute or chronic interstitial pneumonitis, often associated with blood eosinophilia, may occur and deaths have been reported. Symptoms typically include dyspnoea, cough (especially a dry non-productive cough) and fever for which patients should be monitored at each follow-up visit. Patients should be informed of the risk of pneumonitis and advised to contact their doctor immediately should they develop persistent cough or dyspnoea. Methotrexate may be hepatotoxic, particularly at high dosage or with prolonged therapy. Liver atrophy, necrosis, cirrhosis, fatty changes, and periportal fibrosis have been reported. Bone marrow suppression (avoid concomitant use with another anti-folate drug (e.g. trimethoprim)) and gastrointestinal disturbance (nausea and abdominal discomfort) may also be seen as adverse drug reactions with methotrexate therapy.

Please also see Summary of Product Characteristics (SmPC), Investigator Brochure (IB) and Package Insert for expected adverse events for rituximab, active comparators and glucocorticoids.

**13.3 Expected Serious Adverse Events**

The following are expected adverse events that may occur after the administration of rituximab.

*Infusion reactions* – fever, chills, rash, pruritis, flushing, throat irritation, angioedema, nausea and vomiting, fatigue, headache, hypotension and bronchospasm. Mild infusion reactions are common, and can be treated by stopping the infusion, and restarting at a lower rate, together with antihistamine, antiemetic and paracetamol. Severe infusion reactions have occurred but are rare. Hydrocortisone and adrenaline should be available for administration if needed (as per hospital protocol). Following a moderate or severe infusion reaction, patients should be admitted to hospital for observation.

*Bone marrow suppression* – leucopenia and neutropenia

*Infections* – including reaction of hepatitis B, and PML (progressive multifocal leucoencephalopathy caused by reactivation of the JC virus)
These must be documented in the CRFs and if discontinuation of rituximab is being considered, then the TMC must be consulted.

Expected serious adverse events may be disease-related, treatment-related or other events, and may be related to rituximab and/or to other drugs used to treat vasculitis within the protocol, e.g. glucocorticoids.

### 13.4 Recording and Evaluation of Adverse Events

Individual adverse events should be evaluated by the investigator. This includes the evaluation of its seriousness, causality and any relationship between the investigational medicinal product(s) and/or concomitant therapy and the adverse event.

#### 13.4.1 Assessment of seriousness

Seriousness is assessed against the criteria in section 13.1.4. This defines whether the event is an adverse event, serious adverse event or a serious adverse reaction.

#### 13.4.2 Assessment of causality

- **Definitely:** A causal relationship is clinically/biologically certain. **This is therefore an Adverse Reaction**
- **Probable:** A causal relationship is clinically/biologically highly plausible and there is a plausible time sequence between onset of the AE and administration of the investigational medicinal product and there is a reasonable response on withdrawal. **This is therefore an Adverse Reaction.**
- **Possible:** A causal relationship is clinically/biologically plausible and there is a plausible time sequence between onset of the AE and administration of the investigational medicinal product. **This is therefore an Adverse Reaction.**
- **Unlikely:** A causal relation is improbable and another documented cause of the AE is most plausible. **This is therefore an Adverse Event.**
- **Unrelated:** A causal relationship can be definitely excluded and another documented cause of the AE is most plausible. **This is therefore an Adverse Event.**

#### 13.4.3 Clinical assessment of severity

- **Mild:** The subject is aware of the event or symptom, but the event or symptom is easily tolerated
- **Moderate:** The subject experiences sufficient discomfort to interfere with or reduce his or her usual level of activity
- **Severe:** Significant impairment of functioning; the subject is unable to carry out usual activities and/or the subject’s life is at risk from the event.

#### 13.4.4 Toxicity assessment

Toxicity grades will be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) ([http://ctep.cancer.gov/reporting/ctc.html](http://ctep.cancer.gov/reporting/ctc.html)). The purpose of using the CTCAE system is to provide a standard language to describe toxicities, to facilitate tabulation and analysis of the data and to facilitate the assessment of the clinical significance of all adverse events. The CTCAE provides the following grade and descriptions in the CTCAE manual (v3.0). Adverse events should be recorded and graded 1 to 5 according to the CTCAE grade provided below:

- Grade 1 = mild adverse event
Grade 2 = moderate adverse event
Grade 3 = severe and undesirable adverse event
Grade 4 = life-threatening or disabling adverse event
Grade 5 = death

13.5 Reporting Serious Adverse Events
All Serious Adverse Events must be reported to the central trials co-ordinator, within 24 hours of the investigator becoming aware of the event. Cumulative safety reports will be generated and sent monthly to the sponsor and the TMC, and every three months to all Principal Investigators.

Each Principal Investigator will record serious adverse events (SAE) on a designated SAE form and report these to the Chief Investigators within 24 hours. The Chief Investigators are responsible for assessing all SAEs for expectedness and the prompt notification of all SAEs to the Sponsor. The sponsor has to keep detailed records of all SAEs reported to them by the trial team.

The Chief Investigator is also responsible for prompt reporting of all serious adverse events to the competent authority (e.g. MHRA) of each concerned country of findings that could adversely affect the health of subjects, impact on the conduct of the trial or alter the competent authority’s authorization to continue the trial in accordance with local regulations. The Chief Investigator may delegate the responsibility for reporting serious adverse events to the competent authority of any concerned country outside the UK to a local lead investigator. This will be recorded and agreed in the participating site agreement to be put in place between the Sponsor and the local lead site.

An adverse event or reaction that meets serious criteria irrespective of consistency (expected or unexpected) with the applicable product information (e.g. investigators brochure for unapproved investigational product or summary of product characteristics) must be reported to the sponsor unless explicitly listed within the protocol.

13.6 Reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs)
All suspected adverse reactions related to an investigational medicinal product (the tested IMP and comparators) which occur in the concerned trial, and that are both unexpected and serious (SUSARs) are subject to expedited reporting.

13.6.1 Who should report and whom to report to?
The Sponsor delegates the responsibility of notification to the Competent Authority (CA), Ethics Committee (EC) and any other investigators to the Chief Investigator. The Chief Investigator should report all the relevant safety information previously described, to the Sponsor, concerned competent authorities and to the Ethics Committee concerned. The Chief Investigator shall inform all investigators concerned of relevant information about SUSARs that could adversely affect the safety of subjects.

13.6.2 When and what events to report?
13.6.2.1 Fatal or life-threatening SUSARs
The CA, Research Ethics Committee and Sponsor should be notified within as soon as possible but no later than 7 calendar days after the trial team and Sponsor has first knowledge of the minimum criteria for expedited reporting.

In each case relevant follow-up information should be sought and a report
completed as soon as possible. It should be communicated to the CA, Ethics Committee and Sponsor within an additional 8 calendar days.

In addition to the timelines above, investigators should be aware of, and comply with, the reporting timelines in their respective countries.

13.6.2.2 Non fatal and non life-threatening SUSARs

All other SUSARs and safety issues must be reported to the competent authority and Ethics Committee in the concerned country as soon as possible but no later than 15 calendar days after first knowledge of the minimum criteria for expedited reporting. Further relevant follow-up information should be given as soon as possible.

13.6.2.3 Infections

Infections requiring treatment with intravenous (IV) or oral antibiotics or infections commonly understood as opportunistic will fall within the 15 calendar day reporting period.

13.6.2.4 Non serious adverse events/reactions

Expected or unexpected AEs/ARs that are grade 1 or grade 2 will not be collected or reported.

13.6.3 How to report?

13.6.3.1 Minimum criteria for initial expedited reporting of SUSARs

Information on the final description and evaluation of an adverse reaction report may not be available within the required time frames for reporting. For regulatory purposes, initial expedited reports should be submitted within the time limits as soon as the minimum following criteria are met:

a) A suspected investigational medicinal product,

b) An identifiable subject (e.g. trial subject code number),

c) An adverse event assessed as serious and unexpected, and for which there is a reasonable suspected causal relationship,

d) An identifiable reporting source, and, when available and applicable:

- A unique clinical trial identification (EudraCT number or in case of non-European Community trials the sponsor's trial protocol code number)

- A unique case identification (i.e. sponsor's case identification number).

13.6.3.2 Follow-up reports of SUSARs

In case of incomplete information at the time of initial reporting, all the appropriate information for an adequate analysis of causality should be actively sought from the reporter or other available sources. Further available relevant information should be reported as follow-up reports. In certain cases, it may be appropriate to conduct follow-up of the long-term outcome of a particular reaction.

13.6.3.3 Format of the SUSARs reports

Electronic reporting, when available, is the expected method for expedited reporting of SUSARs to the CA. The format and content as defined by the CA should be adhered to.
14  Toxicity – Emergency Procedures

In the event of toxicity reactions, standard medical practices will be employed, including emergency care and hospitalization if needed. All medications in this study are licensed for use in medicine and their uses are familiar to the physicians and staff at all participating centres.

15  Evaluation of Results

The primary endpoint is the time to relapse (including both major and minor – see definitions in section 15.1) from randomisation. This will be reported when all subjects have completed the 24 month treatment phase of the study.

15.1 Response Criteria

15.1.1 Remission

For the purpose of this study, and progression to randomisation for allocation to one of the two arms of the maintenance phase of the study, remission equates to achievement of disease control (defined as a BVAS/WG ≤ 1 and daily prednisone dose ≤ 10mg) by month 4.

15.1.2 Major relapse

Major relapse is defined as the development of a new or recurrent major disease activity item using the BVAS/WG that in the opinion of the investigator requires treatment with > prednisone 20mg/day for any period of time and/or increase in dose of immunosuppressive medication and/or addition or substitution of another immunosuppressive medication.

Subjects experiencing a major relapse will have met the end point of the trial. Further treatment decisions are made by the investigator and are not determined by the protocol. All patients will continue to be followed for safety purposes.

15.1.3 Minor relapse

Minor Relapse = "Any increase in disease activity that does not meet the definition of Major Relapse."

Although subjects experiencing a minor relapse will have met the trial end-point they will remain in the trial on the following protocol (Relapse Schedule): minor relapses will be treated with an increase in prednisone to 20 mg/day for 7 days, reducing to 15 mg/day for 7 days, 10mg/day for 7 days and then back to 5mg/day.

Treatment of a minor relapse will be allowed only once during the trial period. At the time of a second minor relapse, further treatment decisions are made by local investigators and are not determined by the protocol. All patients will continue to be followed for safety purposes.

16  Statistics

16.1 Statistical Methods

The study will have a 24 month recruitment period. The minimum follow-up period will be 24 months of treatment plus 12 months post-treatment, totalling 36 months. The maximum follow-up period will be 24 months of treatment plus 24 moths post-treatment, totalling 48 months.
The primary intention to treat analysis will be based on a Cox proportional hazard model. There will be a closed testing procedure, first the null hypothesis will be for a hazard ratio of 1 at all time points. If this is rejected at a 5% level then two further sub-hypotheses will be examined using time-varying covariates:

1. A hazard ratio of 1 up to 24 months post-randomisation (i.e. during treatment).
2. A hazard ratio of 1 after 24 months post-randomisation (i.e. post-treatment).

A detailed statistical analysis plan will be produced before the final data base lock and this plan will include sub-group analyses and handling of missing or spurious data.

16.2 Interim Analyses
No interim analyses are planned, but an independent Data Monitoring Committee (Data and Safety Monitoring Board) will be convened to review efficacy and safety data, and will advise on the need for any additional analyses or alterations to the conduct or even continuation of the trial if there are major safety concerns. A blinded Independent Adjudication Committee will be convened to look at the data after the first 10 cases of relapse as per protocol definition.

16.3 Number of Subjects to be Enrolled
Enrolment will be ongoing until 160 patients are randomised. We anticipate this will require 190 patients to be recruited. Any patients in the induction phase when enrolment is halted will continue to follow the protocol and be randomised if the relevant criteria are met.

A power of 90% is achieved under the alternative hypothesis of a hazard ratio of 0.42 at the 5% significance level with 58 observed relapses. Randomising 160 patients will achieve this over the course of the study assuming a drop-out rate up to 5% at 2 years and a relapse-free rate of 75% and 50% at 4 years in the experimental and control arms respectively.

Based on data from the Cambridge cohort study, the overall hazard ratio is estimated (95% confidence interval) as 0.230 (0.116, 0.458) based on 37 observed relapses. For the early period the hazard ratio estimate is 0.210 (0.098, 0.449) based on 30 observed relapses. For the late period the hazard ratio estimate is 0.323 (0.061, 1.729) based on seven observed relapses. Hence the sample size/power calculations are robust as they are based on a hazard ratio of 0.42 under the alternative hypothesis; the value of 0.42 is at the upper end of the confidence intervals for the overall and early period hazard ratios from the pilot data. We have based our projected drop-out rate based on the recently published EUVAS IMPROVE trial (14). It justifies the assumption of a rate below 5% in the second year.

16.4 Criteria for the Termination of the Trial
The trial may be discontinued in the event of clear evidence of harm or benefit for one treatment regimen on the recommendation of the DMC/DSMB and in conjunction with the Trial Management Committee. Safety data will be reviewed by the DMC/DSMB on an annual basis. The trial is planned to close 36 months after the final patient is enrolled (common closing date).

16.5 Procedure to Account for Missing or Spurious Data
A detailed statistical analysis plan will be produced before the final data base lock and this plan will include sub-group analyses. The only aspect of missing data that will affect the primary analysis is the handling of patients who drop out before the scheduled study close; the process for handling such events is given in the definition of the primary endpoint in section 9.6.1.
16.6 Definition of the End of the Trial
The trial will end when the final patient has completed 12 months of follow up (has been in the trial for 36 months in total).

17 Data Handling and Record Keeping

17.1 CRF
All data will be transferred into a Case Report Form (CRF) which will be anonymised. All trial data in the CRF must be extracted from and be consistent with the relevant source documents. The CRFs must be completed, dated and signed by the investigator or designee in a timely manner. It remains the responsibility of the investigator for the timing, completeness, legibility and accuracy of the CRF pages. The CRF will be accessible to trial coordinators, data managers and the investigators as required.

All CRF pages must be clear, legible and completed in black ink. Any errors should be crossed with a single stroke so that the original entry can still be seen. Corrections should be inserted and the change dated and initialled by the investigator or designee. If it is not clear why the change has been made, an explanation should be written next to the change. Typing correction fluid must not be used. Changes must not be made to the CRF pages once the original has been returned to the trial coordination centre.

Completed CRF pages should be returned to the trial coordinating centre within 2 weeks of the evaluations.

17.2 Source Data
To enable monitoring, audit and/or inspection the investigator must agree to keep records of all participating patients (sufficient information to link records e.g., CRFs, hospital records and samples), all original signed informed consent forms and copies of the CRF pages. Data sources will include patient medical records and on-line test results.

17.3 Data Protection
All investigators and trial site staff involved in this trial must comply with the requirements of the Data Protection Act 1998 or applicable local laws for sites outside the UK and Trust/Institution Policy with regards to the collection, storage, processing and disclosure of personal information and will uphold the Act’s core principles.

18 Data Monitoring Committee/Trial Steering Committee
The NIH-sponsored VCRC Data and Safety Monitoring Committee will provide oversight of this study. This is a standing DSMB that provides such oversight for existing VCRC studies of vasculitis, including randomised controlled interventional studies. A comprehensive charter for this study will be drafted and implemented prior to the start of the study. It is anticipated that the DSMB will meet at least 6 monthly to discuss the study progress and more frequently, if needed.

19 Ethical & Regulatory Considerations

19.1 Consent
The Informed Consent form must be approved by the EC and must be in compliance with ICH GCP, local regulatory requirements and legal requirements. The investigator must ensure that each trial participant is fully informed about the nature and objectives of the trial and possible risks associated with their participation.
The investigator will obtain written informed consent from each patient before any trial-specific activity is performed. The informed consent form used for this trial and any change made during the course of this trial, must be prospectively approved by the EC. The investigator will retain the original of each patients signed informed consent form in the Investigator Site File (ISF).

Should a patient require a translation of the trial documentation by a locally approved interpreter/translator, it is the responsibility of the individual investigator to use locally approved translators.

All trial documentation in a different language (other than English), including the translation and back translation of documents must be reviewed and approved by the Sponsor prior to use. All sections of the approved documents must appear in the translation. The translated version must be appropriately dated and include version control.

19.2 Ethical Committee Review
Before the start of the trial or implementation of any amendment we will obtain approval of the trial protocol, protocol amendments, participant Information sheet, informed consent forms and other relevant documents e.g., advertisements and GP information letters if applicable from the EC. All correspondence with the EC will be retained in the Trial Master File/Investigator Site File.

Annual reports will be submitted to the EC in accordance with national requirements. It is the Chief Investigators responsibility to produce the annual reports as required.

19.3 Regulatory Compliance
The trial will not commence until a Clinical Trial Authorisation (CTA) is obtained from the relevant Competent Authority for example the MHRA or FDA. The protocol and trial conduct in the UK will comply with the Medicines for Human Use (Clinical Trials) Regulations 2004 and any relevant amendments. For sites outside the UK, the trial will be conducted in accordance with the applicable local regulatory requirements and laws.

Annual Safety Reports will be submitted to the relevant Competent Authority in accordance with national requirements. It is the Chief Investigators responsibility to produce the annual reports as required.

19.4 Trial Documentation Amendments
Trial documentation amendments including protocol amendments must be reviewed and agreement received from the Sponsor for all proposed amendments prior to submission to the EC and/or relevant Competent Authority.

The only circumstance in which an amendment may be initiated prior to EC and/or relevant Competent Authority approval is where the change is necessary to eliminate apparent, immediate risks to the patients (Urgent Safety Measures). In the case, accrual of new patients will be halted until the EC and/or relevant Competent Authority approval has been obtained.

19.5 Peer Review
The trial protocol has been designed by the Trial Steering Committee. The protocol has been reviewed by representatives of Genentech. Input from members of the VCRC and EUVAS has been sought and incorporated.
19.6 Declaration of Helsinki and ICH Good Clinical Practice
The trial will be performed in accordance with the spirit and the letter of the declaration of Helsinki, the ICH Good Clinical Practice Guidelines (CPMP/ICH/135/95), the protocol and applicable local regulatory requirements and laws.

19.7 GCP Training
All trial staff must hold evidence of appropriate GCP training (or local equivalent) or undergo GCP training (or local equivalent) prior to undertaking any responsibilities on this trial. This training should be updated every 2 years or in accordance with your Trust/Institution’s policy.

20 Sponsorship, Financial and Insurance
The trial will be sponsored by Cambridge University Hospitals NHS Foundation Trust except in the US and Canada, where it will be sponsored by the University of Pennsylvania (North American Sponsor).

Funding sources for this trial include: Arthritis Research UK, U.S. National Institutes of Health, and Roche/Genentech

Cambridge University Hospitals NHS Foundation Trust, as a member of the NHS Clinical Negligence Scheme for Trusts, will accept full financial liability for harm caused to participants in the clinical trial caused through the clinical negligence of its employees and honorary contract holders. There are no specific arrangements for compensation should a participant be harmed through participation in the trial, but no-one has acted negligently.

21 Monitoring, Audit & Inspection
The investigator must make all trial documentation and related records available should a CA Inspection occur. Should a monitoring visit or audit be requested, the investigator must make the trial documentation and source data available to the Sponsor’s representative. All patient data must be handled and treated confidentially.

A trial monitor will be based at Addenbrooke’s Hospital, Cambridge, UK for the 2 year recruitment period and 2 year treatment phase of the study. The majority of monitoring will be performed remotely, by analysis CRF returns and SAE documentation. However, the following criteria will trigger a monitoring visit
  1. A particularly high recruitment rate
  2. A high number or consistent late reporting of SAEs
  3. Repeated protocol deviations

We anticipate that about 10% of sites will require a monitoring visit.

22 Protocol Compliance and Breaches of GCP
The investigator must not implement any deviation from the protocol without formal written agreement from the Sponsor and Chief Investigator. If this necessitates a subsequent protocol amendment, or halt to the trial this should be submitted to the EC, CA & Trust/Institution for review and approval if appropriate.

Potential/suspected serious breach of GCP must be reported immediately to the Sponsor.
23  Publications Policy

Ownership of the data arising from this trial resides with the Sponsor. On completion of the trial the data will be analysed and tabulated and a Clinical Study Report prepared by the Trial Management Committee. All investigators participating in the study will be credited. Anonymous Trial data will be shared with Roche/Genentech at three time points: when all patients have completed the induction phase; when all patients have completed the maintenance phase and on completion of the study. All publications need to be reviewed by the Sponsor before being submitted. The Sponsor will provide Roche with details of any publications or presentations for review 45 days in advance of submission.

24  Publications


### 25. Appendices

#### 25.1 Appendix 1: Schedule of events

<table>
<thead>
<tr>
<th>Study Date</th>
<th>Screen</th>
<th>M0</th>
<th>M1.5</th>
<th>M3</th>
<th>M4 (R)</th>
<th>M8</th>
<th>M12</th>
<th>M16</th>
<th>M20</th>
<th>M24</th>
<th>M27</th>
<th>M30</th>
<th>M36</th>
<th>Every 6 months thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td>M=Month R = Randomisation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility Review</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed Consent</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline medical history</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Follow up medical history</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Concomitant meds</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BVAS/WG</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CDA</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF-36, EQ5D</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse event review</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Clinical Labs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FBC/CBC</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ESR</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry (electrolytes, creatinine, LFTs)</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CRP</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ANCA</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Urinalysis</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Lymphocyte markers</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Immunoglobulin’s</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Research Specimens</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Plasma</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>DNA</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RNA</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>